Klinik und Poliklinik für Urologie, Johannes-Gutenberg-Universität, Langenbeckstrasse 1, 55131, Mainz, Deutschland.

This email address is being protected from spam bots, you need Javascript enabled to view it

To date there has been no accepted standard for second-line chemotherapy in docetaxel-refractory patients with metastatic hormone-refractory prostate cancer (mHRPC). Therefore, we evaluated our experience with mitoxantrone plus prednisone (MP) in this setting.

Ten patients with docetaxel-refractory mHRPC were treated with MP. The parameters under investigation were prostate-specific antigen (PSA) remission, biochemical progression-free survival, and pain reduction under chemotherapy.

Partial PSA remission was seen in two patients, "stable disease" in three patients, and progression in five patients receiving MP. Progression-free survival was 8 months (mean) for patients with partial PSA remission and 2 months (median) for patients with "stable disease." Four of seven patients experienced pain reduction with MP. Grade 4 neutropenia was noted in only 10%. Patients with a decline of PSA under docetaxel and MP had a progression-free survival of 11.5 months (median).

Presently, we see the indication for MP as being second-line chemotherapy in docetaxel-refractory patients with mHRPC who cannot be included in phase II/III studies. Even with only a moderate rate of partial PSA remission, every second patient had an improvement in tumor-related pain. Progression-free survival was prolonged, and the side effects of MP were comparatively low.

Article in German

Written by:
Thomas C, Hadaschik BA, Thüroff JW, Wiesner C.   Are you the author?

Reference:
Urologe A. 2009 Jun 5. Epub ahead of print.
doi:10.1007/s00120-009-2006-4

PubMed Abstract
PMID:19513599

UroToday.com Prostate Cancer Section